155 related articles for article (PubMed ID: 38495245)
21. Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders.
Delaby C; Alcolea D; Carmona-Iragui M; Illán-Gala I; Morenas-Rodríguez E; Barroeta I; Altuna M; Estellés T; Santos-Santos M; Turon-Sans J; Muñoz L; Ribosa-Nogué R; Sala-Matavera I; Sánchez-Saudinos B; Subirana A; Videla L; Benejam B; Sirisi S; Lehmann S; Belbin O; Clarimon J; Blesa R; Pagonabarraga J; Rojas-Garcia R; Fortea J; Lleó A
Sci Rep; 2020 Jun; 10(1):9161. PubMed ID: 32514050
[TBL] [Abstract][Full Text] [Related]
22. The diagnosis of progressive supranuclear palsy: current opinions and challenges.
Ali F; Josephs K
Expert Rev Neurother; 2018 Jul; 18(7):603-616. PubMed ID: 29902389
[TBL] [Abstract][Full Text] [Related]
23. Cathepsin S increases tau oligomer formation through limited cleavage, but only IL-6, not cathespin S serum levels correlate with disease severity in the neurodegenerative tauopathy progressive supranuclear palsy.
Nübling G; Schuberth M; Feldmer K; Giese A; Holdt LM; Teupser D; Lorenzl S
Exp Brain Res; 2017 Aug; 235(8):2407-2412. PubMed ID: 28493068
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias.
Baiardi S; Quadalti C; Mammana A; Dellavalle S; Zenesini C; Sambati L; Pantieri R; Polischi B; Romano L; Suffritti M; Bentivenga GM; Randi V; Stanzani-Maserati M; Capellari S; Parchi P
Alzheimers Res Ther; 2022 Oct; 14(1):153. PubMed ID: 36221099
[TBL] [Abstract][Full Text] [Related]
25. Open-Label Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy.
VandeVrede L; Dale ML; Fields S; Frank M; Hare E; Heuer HW; Keith K; Koestler M; Ljubenkov PA; McDermott D; Ohanesian N; Richards J; Rojas JC; Thijssen EH; Walsh C; Wang P; Wolf A; Quinn JF; Tsai R; Boxer AL
Mov Disord Clin Pract; 2020 May; 7(4):440-447. PubMed ID: 32373661
[TBL] [Abstract][Full Text] [Related]
26. Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy.
Brendel M; Barthel H; van Eimeren T; Marek K; Beyer L; Song M; Palleis C; Gehmeyr M; Fietzek U; Respondek G; Sauerbeck J; Nitschmann A; Zach C; Hammes J; Barbe MT; Onur O; Jessen F; Saur D; Schroeter ML; Rumpf JJ; Rullmann M; Schildan A; Patt M; Neumaier B; Barret O; Madonia J; Russell DS; Stephens A; Roeber S; Herms J; Bötzel K; Classen J; Bartenstein P; Villemagne V; Levin J; Höglinger GU; Drzezga A; Seibyl J; Sabri O
JAMA Neurol; 2020 Nov; 77(11):1408-1419. PubMed ID: 33165511
[TBL] [Abstract][Full Text] [Related]
27. Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy.
Schirinzi T; Sancesario GM; Di Lazzaro G; Scalise S; Colona VL; Imbriani P; Mercuri NB; Bernardini S; Lang AE; Pisani A
J Neural Transm (Vienna); 2018 Sep; 125(9):1373-1379. PubMed ID: 29948175
[TBL] [Abstract][Full Text] [Related]
28. Whole-Brain Magnetic Resonance Spectroscopy Reveals Distinct Alterations in Neurometabolic Profile in Progressive Supranuclear Palsy.
Klietz M; Mahmoudi N; Maudsley AA; Sheriff S; Bronzlik P; Almohammad M; Nösel P; Wegner F; Höglinger GU; Lanfermann H; Ding XQ
Mov Disord; 2023 Aug; 38(8):1503-1514. PubMed ID: 37289057
[TBL] [Abstract][Full Text] [Related]
29. The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias.
Abu-Rumeileh S; Capellari S; Stanzani-Maserati M; Polischi B; Martinelli P; Caroppo P; Ladogana A; Parchi P
Alzheimers Res Ther; 2018 Jan; 10(1):3. PubMed ID: 29368621
[TBL] [Abstract][Full Text] [Related]
30. Cutaneous sensory and autonomic denervation in progressive supranuclear palsy.
Dubbioso R; Provitera V; Vitale F; Stancanelli A; Borreca I; Caporaso G; De Michele G; De Rosa A; Picillo M; Barone P; Iodice R; Manganelli F; De Michele G; Santoro L; Nolano M
Neuropathol Appl Neurobiol; 2021 Aug; 47(5):653-663. PubMed ID: 33421177
[TBL] [Abstract][Full Text] [Related]
31. Association of Progressive Supranuclear Palsy Rating Scale with Progressive Supranuclear Palsy Quality of Life Scale.
Pantelyat A; Higginbotham L; Rosenthal L; Lanham D; Nesspor V; AlSalihi M; Bang J; Wang J; Albert M
Neurodegener Dis; 2020; 20(4):139-146. PubMed ID: 33789283
[TBL] [Abstract][Full Text] [Related]
32. Clinical Phenotypes of Progressive Supranuclear Palsy-The Differences in Interleukin Patterns.
Madetko-Alster N; Otto-Ślusarczyk D; Wiercińska-Drapało A; Koziorowski D; Szlufik S; Samborska-Ćwik J; Struga M; Friedman A; Alster P
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894815
[TBL] [Abstract][Full Text] [Related]
33. Association of Neurofilament Light Chain, [
Palleis C; Franzmeier N; Weidinger E; Bernhardt AM; Katzdobler S; Wall S; Ferschmann C; Harris S; Schmitt J; Schuster S; Gnörich J; Finze A; Biechele G; Lindner S; Albert NL; Bartenstein P; Sabri O; Barthel H; Rupprecht R; Nuscher B; Stephens AW; Rauchmann BS; Perneczky R; Haass C; Brendel M; Levin J; Höglinger GU
Neurology; 2024 Jan; 102(1):e207901. PubMed ID: 38165362
[TBL] [Abstract][Full Text] [Related]
34. Pyramidal system involvement in progressive supranuclear palsy - a clinicopathological correlation.
Stejskalova Z; Rohan Z; Rusina R; Tesar A; Kukal J; Kovacs GG; Bartos A; Matej R
BMC Neurol; 2019 Mar; 19(1):42. PubMed ID: 30894142
[TBL] [Abstract][Full Text] [Related]
35. Blood based biomarkers for movement disorders.
Morris HR
Acta Neurol Scand; 2022 Oct; 146(4):353-361. PubMed ID: 36156206
[TBL] [Abstract][Full Text] [Related]
36. Differential Diagnosis of Rare Subtypes of Progressive Supranuclear Palsy and PSP-Like Syndromes-Infrequent Manifestations of the Most Common Form of Atypical Parkinsonism.
Krzosek P; Madetko N; Migda A; Migda B; Jaguś D; Alster P
Front Aging Neurosci; 2022; 14():804385. PubMed ID: 35221993
[TBL] [Abstract][Full Text] [Related]
37. The midbrain-to-pons ratio distinguishes progressive supranuclear palsy from non-fluent primary progressive aphasias.
Silsby M; Tweedie-Cullen RY; Murray CR; Halliday GM; Hodges JR; Burrell JR
Eur J Neurol; 2017 Jul; 24(7):956-965. PubMed ID: 28510312
[TBL] [Abstract][Full Text] [Related]
38. Comparison of autonomic dysfunction in patients with Parkinson's Disease, progressive supranuclear palsy, and multiple system atrophy.
Malkiewicz JJ; Siuda J
Neurol Neurochir Pol; 2024; 58(2):193-202. PubMed ID: 38148738
[TBL] [Abstract][Full Text] [Related]
39. PET Tau Imaging and Motor Impairments Differ Between Corticobasal Syndrome and Progressive Supranuclear Palsy With and Without Alzheimer's Disease Biomarkers.
Vasilevskaya A; Taghdiri F; Multani N; Anor C; Misquitta K; Houle S; Burke C; Tang-Wai D; Lang AE; Fox S; Slow E; Rusjan P; Tartaglia MC
Front Neurol; 2020; 11():574. PubMed ID: 32754109
[No Abstract] [Full Text] [Related]
40. [
Brendel M; Schönecker S; Höglinger G; Lindner S; Havla J; Blautzik J; Sauerbeck J; Rohrer G; Zach C; Vettermann F; Lang AE; Golbe L; Nübling G; Bartenstein P; Furukawa K; Ishiki A; Bötzel K; Danek A; Okamura N; Levin J; Rominger A
Front Aging Neurosci; 2017; 9():440. PubMed ID: 29387005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
